Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

Yan, Binjun; Chen, Xueyan; Ye, Li‐Ran; Chen, Jiaqi; Zheng, Min; Man, Xiao‐Yong

doi:10.3389/fmed.2021.649408

Cited by 30 publications

(36 citation statements)

References 76 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, although biological mechanisms regarding the association have not been clarified, hypotheses relate primarily to the common proinflammatory cytokines and abnormal visceral adipose tissue involved in the pathogenesis of the two diseases ( 12 – 15 ). As psoriasis is currently being considered a systemic disease ( 27 ), in patients with psoriasis, the stimulation of keratinocytes activates chronic inflammation ( 28 , 29 ), leading to the infiltration of dendritic cells, T lymphocytes, macrophages, and neutrophils, which in turn triggers the secretion of proinflammatory interleukin (IL)-17 cytokines. Psoriasis and NAFLD are both affected by the proinflammatory T-helper (Th)17 axis, leading to a shared mechanism in pathogenesis.…”

Section: Discussionmentioning

confidence: 99%

Bidirectional Association Between Psoriasis and Nonalcoholic Fatty Liver Disease: Real-World Evidence From Two Longitudinal Cohort Studies

et al. 2022

View full text Add to dashboard Cite

BackgroundAssociation between nonalcoholic fatty liver disease (NAFLD) and future psoriasis has not yet been confirmed, although the two diseases partially share a common pathogenesis pathway. Studies have revealed an association between psoriasis and subsequent NAFLD; however, these studies were limited to small sample sizes and a cross-sectional study design. Hence, the main objective of this population-based longitudinal cohort study was to evaluate the bidirectional association between psoriasis and NAFLD.MethodsData were retrieved from Taiwan’s National Health Insurance Research Database. Patients with new-onset NAFLD and psoriasis were respectively enrolled in two cohorts. For each comparison cohort, propensity-score-matched controls with no record of NAFLD or psoriasis were selected. An adjusted hazard ratio (aHR) was applied to evaluate subsequent risks.ResultsThe risk of patients with new-onset NAFLD developing psoriasis was statistically significant, with an HR of 1.07 (95% CI, 1.01–1.14). For younger patients with NAFLD, the risk of developing psoriasis was 1.3-fold higher. The risk of patients with new-onset psoriasis developing NAFLD in the future was 1.28-fold higher than that of patients without psoriasis (95% CI, 1.21–1.35), and patients in younger psoriasis subgroups below the age of 40 years were at a higher risk than those in older subgroups, with an aHR of 1.55 (95% CI, 1.40–1.71).ConclusionEvidence supports a bidirectional association between NAFLD and psoriasis, especially in patients below the age of 40 years. The correlation between the two diseases and the subsequent risk of disease development should be considered when caring for patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Bidirectional Association Between Psoriasis and Nonalcoholic Fatty Liver Disease: Real-World Evidence From Two Longitudinal Cohort Studies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It was found that 37.2% of patients with psoriasis had hypocalcemia, while the probability of hypocalcemia in the control group was much lower than that in the psoriasis group (37.2% vs. 9.0%) [ 6 ]. Psoriasis, an important systemic inflammatory disease, may have a common pathogenesis with metabolic diseases such as diabetes, insulin resistance, obesity, and cardiovascular disease, leading to multiple complications in such patients [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Value of Vitamin D, Trace Elements, Glucose, and Lipid Metabolism in Diagnosis and Severity Evaluation of Psoriasis

Huang

Su²,

Zhuang

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. The levels of vitamin D, trace elements, and glucose and lipid metabolism in psoriasis were evaluated, and their value in disease diagnosis and severity evaluation was explored. Methods. In this study, the serum trace elements, blood glucose, and blood lipid indexes of 360 patients with psoriasis and 500 healthy subjects were compared and analyzed. Results. The results of 25-(OH) D3, Cu/Zn, and HDL-C in patients with psoriasis were significantly different from those in the control group. With the aggravation of the disease, Psoriasis Area and Severity Index (PASI) was positively correlated with 25-(OH) D3 and HDL-C and negatively correlated with Cu/Zn. The AUC of the three indexes for the diagnosis of psoriasis was 0.899, 0.675, and 0.848, respectively. Conclusion. There are metabolic abnormalities of 25-(OH) D3, Cu/Zn, and HDL-C in patients with psoriasis, and paying attention to these indicators is conducive to the diagnosis of disease.

show abstract

“…Due to the chronic nature of psoriasis [1][2][3], the affected patients may experience several comorbidities (i.e., respiratory [4][5][6][7][8], cardiovascular [9][10][11][12][13] or gastrointestinal ones [14][15][16][17]) and therapy failures [18][19][20][21][22][23][24][25]. Thus, therapeutic strategies play a pivotal in limiting the psoriasis detrimental progression and the quality of life worsening.…”

Section: Introductionmentioning

confidence: 99%

Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

et al. 2022

View full text Add to dashboard Cite

Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combination therapy (rescue therapy) to save the drug that had decreased its efficacy. At the moment no studies focused on combination/rescue therapy of secukinumab, so we performed a 52-weeks multicenter retrospective observational study that involved 40 subjects with plaque psoriasis that experienced a secondary failure and were treated with combination therapy (ciclosporin (n = 11), MTX (n = 15), NB-UVB (n = 7) and apremilast (n = 7)). After 16 weeks of rescue/combination therapy, PASI and a DLQI varied respectively from 8 [7.0–9.0] and 13 [12.0–15.0], to 3 [2.8–4.0] and 3 [2.0–3.3]), suggesting a significant improvement of daily functionality and quality of life. Results were maintained at 52 weeks. No side effects were experienced during the study. Secukinumab remains a safety and effective drug for PsO patients also in the IL-23 and JAK inhibitors era. The rescue therapy is a valid therapeutic option in case of secukinumab secondary failure.

show abstract

Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

Cited by 30 publications

References 76 publications

Bidirectional Association Between Psoriasis and Nonalcoholic Fatty Liver Disease: Real-World Evidence From Two Longitudinal Cohort Studies

Bidirectional Association Between Psoriasis and Nonalcoholic Fatty Liver Disease: Real-World Evidence From Two Longitudinal Cohort Studies

Clinical Value of Vitamin D, Trace Elements, Glucose, and Lipid Metabolism in Diagnosis and Severity Evaluation of Psoriasis

Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

Contact Info

Product

Resources

About